http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109517900-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate | 2018-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109517900-B |
| titleOfInvention | Primer group, reagent and/or kit and system for detecting lung cancer chemotherapy-related genes and application of primer group, reagent and/or kit and system |
| abstract | The invention relates to a primer group, a reagent and/or a kit for detecting lung cancer chemotherapy-related genes, a system and application thereof. The primer group comprises primers for detecting ERCC1, MTHFR, GSTP1, XRCC1, DYNC2H1, ABCB1, CYP2C8 x 3, TP53, NQO1, CBR3, SOD2, CYP2C19, UGT1A1 x 6, TYMS, NT5C2 and CDA gene mutation. The primer group, the reagent, the kit and the system and the application thereof have the advantages of high accuracy, strong specificity, high sensitivity, good precision and the like, and also have the advantages of sample saving, short detection period, simplicity and easiness in operation, convenience in analysis and the like. |
| priorityDate | 2018-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 125.